VAXON BIOTECH
Vaxon Biotech is a developer of therapeutic vaccines designed to offer treatment for cancer. The company's vaccines are developed to treat lung, gastric, prostate, breast, renal, liver and colorectal cancers by stimulating the immune system to recognize and attack human cancer cells without harming normal cells, enabling patients to get treated from cancer and enjoy a healthy life.
VAXON BIOTECH
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2004-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.vaxon-biotech.com
Total Employee:
11+
Status:
Active
Contact:
+330145886762
Technology used in webpage:
WordPress LetsEncrypt Apache PHP OVH Gandi.net DNS
Similar Organizations
Adprotech
Adprotech is develops pharmaceutical products for the treatment of organ transplant rejection, rheumatoid arthritis, bacterial infection.
Apogenix
Apogenix is a biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases.
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
MYR GmbH
MYR is a biotechnology company developing and commercilizing therapeutics for the treatment of chronic hepatitis B and D infections.
Oxford Emergent Tuberculosis Consortium Ltd.
Oxford Emergent Tuberculosis Consortium Ltd. develops advanced vaccine for the prevention of tuberculosis.
WntResearch
WntResearch develops anti-metastatic therapies for the treatment of cancer patients.
Official Site Inspections
http://www.vaxon-biotech.com
- Host name: cluster015.ovh.net
- IP address: 213.186.33.3
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Vaxon Biotech"
Vaxon Biotech - Crunchbase Company Profile & Funding
Vaxon Biotech is a developer of therapeutic vaccines designed to offer treatment for cancer. The company's vaccines are developed to treat lung, gastric, prostate, breast, renal, liver and …See details»
Vaxon Biotech Company Profile 2024: Valuation, …
Information on valuation, funding, cap tables, investors, and executives for Vaxon Biotech. Use the PitchBook Platform to explore the full profile.See details»
VAXON BIOTECH Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for VAXON BIOTECH of MARLY LE ROI, ILE DE FRANCE. Get the latest business insights from Dun & …See details»
Vaxon Biotech - News, Articles etc. - European …
Mar 16, 2016 · News stories and articles referencing Vaxon Biotech on European Pharmaceutical Review Recommended New webinar with Fujifilm: Monocyte activation test (MAT): Insight into examining regulations and markets prospectsSee details»
VAXON BIOTECH Company Profile - Dun & Bradstreet
VAXON BIOTECH. Get a D&B Hoovers Free Trial. Overview Company Description:? Industry: Scientific Research and Development Services , Professional, Scientific, and Technical …See details»
Vaxon Biotech SACA - Company Profile and News - Bloomberg …
Company profile page for Vaxon Biotech SACA including stock price, company news, executives, board members, and contact informationSee details»
Vaxon Biotech - Craft
Vaxon Biotech is a company developing immunotherapy to treat cancer. Its vaccine Vx-001 is used to stimulate the immune system to recognize and attack the cancer cells. The method is …See details»
Vaxon reports positive data from Phase IIb trial of Vx-001 to treat ...
Jun 1, 2017 · French biopharmaceutical firm Vaxon Biotech has reported positive findings from the Phase IIb clinical trial of Vx-001 for the treatment of patients with non-small-cell lung …See details»
Vaxon Biotech - BioCentury Company Profiles - BCIQ
Mar 28, 2016 · Enter a Company name above to access free BCIQ profiles. Website: http://www.vaxon-biotech.com...See details»
Vaxon Biotech's CSO Kostas Kosmatopoulos becomes chief …
Mar 30, 2015 · Konstantinos (Kostas) Kosmatopoulos, a founder of anti-tumor immunotherapy specialist Vaxon Biotech, has become chief executive of the company. He moves from his …See details»
Research programme: cancer vaccines - Vaxon Biotech
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. Vaxon Biotech is developing cancer vaccines that are based on optimised …See details»
Clinical activity of a htert (vx-001) cancer vaccine as post ... - Nature
Mar 25, 2020 · Vx-001 targets TERT (TElomerase Reverse Transcriptase) and has been tested in a basket phase 1/2 clinical study on patients with different tumour types, mainly non-small cell …See details»
Clinical activity of a htert (vx-001) cancer vaccine as post ...
May 5, 2020 · Additional key eligibility criteria included an HLA-A*0201 haplotype and tumoural expression of TERT as assessed by in situ hybridization in a central laboratory (Vaxon …See details»
Vaxon completes enrolment in Phase IIb trial of Vx-001 in NSCLC
Mar 16, 2016 · Vaxon has announced the completion of enrolment for its Phase IIb trial of Vx-001 in non-small-cell lung cancer (NSCLC). Vx-001 is a therapeutic cancer vaccine based on …See details»
Clinical Activity of an hTERT-Specific Cancer Vaccine (Vx-001) in ...
Apr 1, 2021 · Conclusions: These results support the hypothesis that Vx-001 may be efficient in patients with non-immunogenic/cold but not with immunogenic/hot tumors. Keywords: Vx-001; …See details»
Immune responses in cancer patients after vaccination with the ...
May 1, 2008 · Background: Vx-001 (Vaxon Biotech, Genopole, Evry, France), an HLA-A*0201 restricted therapeutic telomerase-specific tumour vaccine is composed of the 9mer cryptic …See details»
Immunological responses in cancer patients after vaccination with …
We have previously shown that Vx-001 is non-toxic, highly immunogenic and in vaccinated NSCLC patients early specific immune response is associated with prolonged survival. The …See details»
Optimized tumor cryptic peptides: the basis for universal neo …
May 15, 2016 · 1 Vaxon Biotech, 3 rue de l'Arrivée 75015, Paris, France. The very impressive clinical results recently obtained in cancer patients treated with immune response checkpoint …See details»
Vx 006 - AdisInsight - Springer
Vx 006 vaccine, is being developed by Vaxon Biotech, for the treatment of solid tumours. Vx 006 is a polypeptide that is composed of three optimised cryptic.See details»
VAXON-BIOTECH ANNOUNCES RESULTS OF IMMUNOTHERAPY …
Vaxon-Biotech has announced the preliminary results of a Phase I trial of its candidate vaccine Vx-001. Based on observations in 27 newly included cancer patients (current total 46 …See details»